Companies › Lixte Biotechnology Holdings
1 active drug program in 4 registered trials: 4 Phase 1; Hematology, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LB-100 Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor; Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor; Serine/threonine-protein phosphatase 5 inhibitor | PPP2CA, PPP2CB, PPP5C | Phase 1 | Myelodysplastic Syndromes; Advanced Soft-tissue Sarcoma; Extensive Stage Lung Small Cell Carcinoma; Metastatic Microsatellite-stable Colorectal Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03886662 | LB-100 | Phase 1 | Myelodysplastic Syndromes | Hematology | May 2021 |
| NCT05809830 | LB-100 | Phase 1 | Advanced Soft-tissue Sarcoma | Oncology | Jun 2025 |
| NCT04560972 | LB-100 | Phase 1 | Extensive Stage Lung Small Cell Carcinoma | Oncology | Jan 2027 |
| NCT06012734 | LB-100 | Phase 1 | Metastatic Microsatellite-stable Colorectal Cancer | Oncology | Jul 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.